InnoOrigin

InnoOrigin is a biotechnology company based in Suzhou, China, focused on the development of next-generation RNA therapeutics utilizing circular RNA (circRNA) technology. The company leverages its proprietary circ-X platform to design and manufacture circRNA molecules that offer significantly enhanced stability and longer-lasting protein expression compared to traditional linear mRNA. InnoOrigin integrates computational RNA design, efficient circularization processes, and advanced lipid nanoparticle (LNP) delivery systems to create its therapeutic candidates. Their current pipeline targets a broad range of applications, including oncology, infectious disease vaccines, and protein replacement therapies for metabolic and rare conditions. By overcoming the limitations of first-generation mRNA, such as rapid degradation and immunogenicity, InnoOrigin aims to deliver more effective and durable treatments to patients worldwide.